GH Earnings Date: Nov 5, 2026 (Estimated) — Guardant Health, Inc.
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is GH's next earnings date?
Guardant Health, Inc. (GH) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.75 on revenue of $350.7M.
How did GH do in its last earnings report?
In its most recent report on Jul 30, 2026 (Q2 2026), Guardant Health, Inc. posted EPS of -$0.42 versus the -$0.46 estimate, a beat of 8.7%. Revenue was $335.0M against a $314.9M estimate. The stock's 1-day post-earnings move was +6.3%.
How much does GH stock move after earnings?
GH beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.3% (up or down) in the day after earnings.
About Guardant Health, Inc.
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | -0.46 | -0.42 | +8.70% | $335.0M | ✅ Beat | +6.33% | +3.43% | +6.01% |
| 2026-05-12 | Q1 2026 | 0.06 | 0.15 | +150.00% | $21.2M | ✅ Beat | -1.47% | -1.75% | +30.98% |
| 2026-02-19 | Q4 2025 | -0.61 | -0.50 | +18.03% | $281.3M | ✅ Beat | -3.08% | -7.91% | -19.93% |
| 2025-10-29 | Q3 2025 | -0.61 | -0.39 | +36.07% | $265.2M | ✅ Beat | +27.87% | +31.52% | +50.02% |
| 2025-07-30 | Q2 2025 | -0.62 | -0.44 | +29.03% | $232.1M | ✅ Beat | -9.32% | -1.33% | +42.66% |
| 2025-04-30 | Q1 2025 | -0.59 | -0.49 | +16.95% | $203.5M | ✅ Beat | +3.47% | -15.86% | -14.00% |
| 2025-02-20 | Q4 2024 | -0.50 | -0.62 | -24.00% | $201.8M | ❌ Miss | -9.56% | -11.16% | -2.74% |
| 2024-11-06 | Q3 2024 | -0.74 | -0.45 | +39.19% | $191.5M | ✅ Beat | +13.05% | +24.99% | +45.79% |
Showing last 8 quarters.